Telehealth Ledger
Enhance.MD logoProvider treatment guide · checked 27 October 2026

Enhance.MD Semaglutide

Published by Telehealth LedgerSource checked 27 October 2026

Enhance.MD lists GLP-1 Core (semaglutide) 1-month at $249 every 4 weeks after $199 for the first period; $270.49 annualized monthly equivalent (365-day basis). Medication is included in that catalog price. Readers comparing Enhance.MD compounded semaglutide who need the 1-month card billed every 4 weeks, the first-order $50 reduction, and the launch-state list instead of the 12-month starting price. The commercial terms were checked 27 October 2026; state access, clinician approval, dispensing details, and personal suitability remain separate questions.

We may earn a commission if you start a program through links on this page. It doesn't change prices or how we sort them. Disclosure

Visit Enhance.MD Affiliate link · we may earn a commissionRead the full review
Enhance.MD Semaglutide treatment illustration
$249every 4 weeks after $199 for the first period; $270.49 annualized monthly equivalent (365-day basis)
Includedmedication in published price
Once-weekly subcutaneous injection, billed every 4 weekslisted format
27 October 2026commercial terms checked
10 listed restrictionspublished state availability

The commercial question this page answers: Enhance.MD Semaglutide

Decide whether Enhance.MD's 1-month GLP-1 Core semaglutide card is the intended purchase, keeping the $249 charge billed every 4 weeks separate from the $212 12-month prepaid homepage card.

Readers comparing Enhance.MD compounded semaglutide who need the 1-month card billed every 4 weeks, the first-order $50 reduction, and the launch-state list instead of the 12-month starting price. This is a commercial fit statement, not a clinical suitability judgment. The linked sources describe the product, format and price on the date checked, while a clinician must decide eligibility.

Start with continuing cost, not the headline: Enhance.MD

Enhance.MD lists GLP-1 Core (semaglutide) 1-month at $249 every 4 weeks after $199 for the first period; $270.49 annualized monthly equivalent (365-day basis), checked 27 October 2026. Read the amount together with the billing interval and any promotion or prepayment shown beside it. A lower monthly equivalent may require a longer commitment and a larger charge today. The linked price source is dated evidence of the advertised offer, not an independently verified checkout total or a guarantee that every dose and plan costs the same.

The published price includes medication. It does not verify that labs, every consultation, supplies, expedited shipping, or future dose changes are included unless the source says so. Those items remain checkout questions. For Enhance.MD Semaglutide, read medication inclusion as one part of the offer, not as proof that every service surrounding the prescription is free. The dated source establishes the advertised basis; it does not independently audit the final checkout, dispensing event, or quality of care.

Route and regulatory status: GLP-1 Core (semaglutide) 1-month

GLP-1 Core (semaglutide) 1-month is listed as a compounded product in Once-weekly subcutaneous injection, billed every 4 weeks format. FDA states that compounded drugs are not FDA-approved and do not receive the same premarket review as approved drug products. Ask for the exact formulation and dispensing pharmacy before purchase. That status is central to this Enhance.MD guide because a related medication name does not make branded, compounded, oral, nasal, and injectable products interchangeable.

Enhance.MD lists GLP-1 Core (semaglutide) 1-month in Once-weekly subcutaneous injection, billed every 4 weeks format. The Compounded semaglutide injection comparison groups offers with the same treatment and route so their prices can be assessed fairly. A shared medication name does not make different formulations interchangeable. This guide does not provide dose instructions or route conversions, and it does not establish that another formulation has the same evidence, safety profile, convenience or outcomes.

Do not infer nationwide access: Semaglutide

Published availability lists Alabama, Arkansas, Georgia, Hawaii, Louisiana, Missouri, Mississippi, North Dakota, South Carolina and Tennessee as restricted for weight-loss programs. That list reflects the sources checked on the date shown; it does not prove eligibility everywhere else. Confirm the current state rule before intake. The Semaglutide access check belongs near the price because a low published figure has little decision value when Enhance.MD cannot serve the reader's state or the selected product cannot be fulfilled there.

For Enhance.MD Semaglutide, the consumer brand, administrative platform, clinical group, and dispensing pharmacy can be different entities. A provider page may describe a national service while licensure, product rules, and pharmacy coverage narrow actual fulfillment. Ask which clinician entity would review the intake and which licensed pharmacy would dispense this exact product in the reader's state before treating access as settled.

Roles, policies, and unresolved facts: Enhance.MD

The linked sources identify Enhance.MD, LLC as Enhance.MD's administrator. Quoted from the terms of service: Enhance.MD, LLC operates the website from 16192 Coastal Highway, Lewes, Delaware 19958. The homepage and terms describe it as a patient-management platform that does not itself provide medical or pharmacy services. These entities can perform different jobs, so the consumer-facing brand should not automatically be described as the clinician or dispensing pharmacy for Semaglutide.

Launch-state list and GLP-1 BMI floors: The FAQ says Enhance.MD is licensed in all 50 states but currently launching in a named list that includes D.C. and excludes AL, AR, GA, HI, LA, MO, MS, ND, SC, and TN. New-patient GLP-1 BMI is 25 or higher; maintenance BMI is 20 or higher. An unresolved issue for Enhance.MD's Semaglutide offer remains: BBB California sole-proprietorship listing does not match the Delaware LLC: BBB lists Enhance MD in Encinitas and San Diego, California as a sole proprietorship started in 2019, not accredited, with phone (888) 299-5088. Official terms identify Enhance.MD, LLC at a Lewes, Delaware address. The phone matches; the legal-entity type and mailing location do not. Ask the provider how that issue affects the selected order. A published price does not resolve uncertainty about billing, fulfillment, eligibility or the terms that apply after payment.

Promotion, renewal, and prepayment: Enhance.MD Semaglutide

The published offer lists $249 every 4 weeks after $199 for the first period; $270.49 annualized monthly equivalent (365-day basis). It does not establish every possible dose, renewal, refund, or future price. Confirm the complete checkout total and next billing date before payment. For Enhance.MD's Semaglutide offer, distinguish the introductory charge, continuing charge, upfront payment and required commitment. A monthly equivalent can be useful, but only when the required payment and term remain visible beside it.

The Enhance.MD price source for this offer was checked on 27 October 2026. Before paying for Semaglutide, compare the amount charged today with the amount charged later, the number of months purchased, the renewal date, the cancellation window, and the refund boundary after clinical or pharmacy processing. A published price cannot safely answer those policy questions unless the cited provider evidence does.

A fair comparison frame: Semaglutide

The linked Semaglutide comparison places Enhance.MD beside other providers with published prices. Check the same details for every offer: continuing price, introductory period, required prepayment, medication inclusion, product type, delivery format, verification date, and state evidence. If two offers use different routes or one price excludes medication, a simple lowest-number verdict would not be a like-for-like conclusion.

Use the comparison link to check other Semaglutide offers, then open Enhance.MD's site to confirm the selected product. A provider may list several related treatments or plan lengths on the same page. Make sure the intake and checkout still name GLP-1 Core (semaglutide) 1-month, use the once-weekly subcutaneous injection, billed every 4 weeks format, and show the same medication inclusion and billing basis before treating the two offers as equivalent.

What to confirm next: Enhance.MD Semaglutide

A place on the Enhance.MD shortlist depends on whether the reader accepts GLP-1 Core (semaglutide) 1-month, the once-weekly subcutaneous injection, billed every 4 weeks format, and the recorded Semaglutide billing basis. A lower apparent number should not override product identity or required commitment.

Readers comparing Enhance.MD compounded semaglutide who need the 1-month card billed every 4 weeks, the first-order $50 reduction, and the launch-state list instead of the 12-month starting price. A sound decision keeps the source date visible and refuses to convert missing operational detail into a favorable assumption.

Common questions

Enhance.MD Semaglutide FAQ

What was verified about cost for Enhance.MD Semaglutide?
The linked price source lists $249 every 4 weeks after $199 for the first period; $270.49 annualized monthly equivalent (365-day basis) for GLP-1 Core (semaglutide) 1-month, checked 27 October 2026. The amount should be read with any introduction, prepayment, or commitment shown in the same offer record. It is a dated published commercial fact, not a promise that every checkout configuration, future renewal, or product change will cost the same amount.
What does included mean here in the Enhance.MD figure?
The published Enhance.MD offer includes medication for Semaglutide. That does not establish that the price includes labs, every consultation, supplies, faster shipping, dose-related price changes, or a future refill. Confirm those items and the complete charge in the selected checkout before treating the figure as all-inclusive.
Why keep the exact product name for Enhance.MD Semaglutide?
This guide covers GLP-1 Core (semaglutide) 1-month in Once-weekly subcutaneous injection, billed every 4 weeks format. It does not transfer price, regulatory status, evidence, convenience, dosing, pharmacy, or fulfillment claims to another Semaglutide formulation or to a related product. Compare route and product identity before comparing the price because similar medication names can still describe materially different offers.
What can limit fulfillment for Enhance.MD Semaglutide?
Published availability lists Alabama, Arkansas, Georgia, Hawaii, Louisiana, Missouri, Mississippi, North Dakota, South Carolina and Tennessee as restricted for this type of treatment. Confirm eligibility directly because provider coverage can change. A published state list is only one part of eligibility. Enhance.MD must also confirm clinician licensure, product eligibility, and pharmacy fulfillment for the specific Semaglutide prescription. Completing an intake does not guarantee approval, dispensing, or a particular outcome.
How should I build a shortlist for Enhance.MD Semaglutide?
Use the Semaglutide comparison to check the dated prices, product formats and plan terms across providers. Compare Enhance.MD only with offers that disclose the same price components, medication inclusion, commitment, and format; otherwise explain why the rows are not directly equivalent.

Sources and method

Telehealth Ledger checked provider pages, plan terms, and independent context on 27 October 2026. This page compares published commercial terms. It is not a rating, medical advice, or a guarantee that a clinician will prescribe treatment.